safety
PT-141 (Vyleesi) Safety Profile
Safety information for FDA-approved PT-141 (bremelanotide/Vyleesi) for HSDD. Complete side effects, warnings, and contraindications from clinical trial data.
PepCodex Research Team
6 min read
#pt-141
#bremelanotide
#vyleesi
#safety
#fda-approved
#hsdd
Safety Overview
PT-141 (Vyleesi) is FDA-approved with established safety data from the RECONNECT Phase 3 trials.
Common Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Nausea | 40% | Most common; often significant |
| Flushing | 21% | Expected from mechanism |
| Injection site reaction | 13% | Pain, redness |
| Headache | 11% | Usually mild |
Serious Warnings
Cardiovascular
- Transient blood pressure increases observed
- Caution in uncontrolled hypertension
- Caution in cardiovascular disease
Focal Hyperpigmentation
- Darkening of face, gums, or breasts possible
- May not resolve after stopping
Drug Interaction
- Do not use with naltrexone (antagonizes effects)
Who Should NOT Use
- Uncontrolled hypertension
- Cardiovascular disease
- Concurrent naltrexone use
- Known hypersensitivity
Usage Limitations
- Maximum 1 dose per 24 hours
- Maximum 8 doses per month
- Not for daily use
Special Populations
- Only approved for premenopausal women
- Not studied in men for this indication
- Not recommended in severe hepatic impairment
This is for educational purposes. PT-141 is a prescription medication for specific indications.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.